Search Results
Your search for The ASCO ,The ASCO matches 20570 pages
Showing 2451 - 2500FDA Grants Approval to Atezolizumab in Treatment of Alveolar Soft-Part Sarcoma
On December 9, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft-part sarcoma (ASPS). Study ML39345 Efficacy was evaluated in Study ML39345...
Putting the Patient at the Center: The Career of Jeffery Ward, MD, FASCO
Editor’s Note: ASCO was deeply saddened by the news that Dr. Jeff Ward passed away on November 3, 2022. In an interview with Dr. Ward this past summer, published in ASCO Connection (August 30, 2022), ASCO recognized Dr. Ward’s commitment to exceptional patient care and public advocacy. An...
I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Experimental Drug Under Study in Liver Cancer
A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer who have been treated unsuccessfully previously with up to three lines of treatment. These findings were presented...
AKT Inhibitor Shows Signs of Activity in a Trial Matching Drugs to Tumor Gene Mutations
In a trial matching the genetic makeup of tumors with new treatments, tumors shrank in 22% of patients with cancer who received the AKT inhibitor ipatasertib. Participants included those with breast cancer and endometrial cancer as well as those with two rarer types of cancer, anal and salivary...
Liquid Biopsies May Identify Patients With Cancer at Higher Risk of Developing Additional Blood Cancers
Researchers have found that liquid biopsies may be able to detect the blood disorder clonal hematopoiesis, which places patients at higher risk of developing blood cancers. The findings were presented at the 2022 European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer...
Education and Diligence Required to Confront the Challenges of Pregnancy-Associated Breast Cancer
Physiologic changes of pregnancy, such as increased breast volume and firmness, present challenges to detecting breast cancer. Meeting those challenges requires “education and continued diligence, both on the patient side as well as on the physician side,” Luis Zabala Blanco, Jr, MD, said in an...
Pregnancy Confers ‘Dual Effect’ on Breast Cancer Risk
“Pregnancy confers a dual effect” on breast cancer risk, “with an initial transient increased risk for breast cancer that is followed by long-term protection over time,” Luis Zabala Blanco, Jr, MD, noted in an update on the pathology of pregnancy-associated breast cancer, which was presented at the ...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
2022 Society for Integrative Oncology Annual International Conference
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its 2022 Annual International Conference in a hybrid format (virtual and in Scottsdale, Arizona). It was centered on the basic science, education and training, and implementation of integrative oncology in diverse...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic...
Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer
Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
Michael A. Caligiuri, MD, Traveled From Humble Beginnings to a Notable Career as an Oncology Leader
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Michael A. Caligiuri, MD, a physician-scientist who currently serves as President of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
AMA House of Delegates Approves ASCO-Backed Resolutions on Fertility Preservation, American-Manufactured Personal Protective Equipment, and Third-Party Pharmacy Benefit Administrators
From November 11 to 15, delegates from ASCO participated in the 2022 Interim Meeting of the American Medical Association’s (AMA) House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and establish policies the AMA uses...
ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer
A new ASCO guideline on the management of advanced colorectal cancer summarizes the latest treatments supported by quality data that could expand oncologists’ armamentarium and potentially improve survival outcomes.1 “[Colorectal cancer] remains the second-leading class of cancer deaths among men ...
Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer
Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the...
Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx
Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed...
Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer
The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative breast cancer provided overall survival benefits compared with physician’s choice of treatment,...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer
The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival compared to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the phase II SERENA-2 trial presented by Mafalda Oliveira, MD,...
Patients With Breast Cancer Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-Term Recurrence Rates
Patients with breast cancer who paused their endocrine therapy while attempting to conceive experienced short-term rates of breast cancer recurrence similar to patients with breast cancer who did not pause their therapy for pregnancy—and many of them went on to conceive and deliver healthy babies,...
Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer
In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant, according to results...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Clinical Implications of Residual Cancer Burden
An exploratory analysis of KEYNOTE-522, which established the benefit of neoadjuvant pembrolizumab plus chemotherapy in triple-negative breast cancer, has now provided data to further describe prognosis and possibly guide treatment.1 In the study, presented at the 2022 ASCO Annual Meeting,...
Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab...
Sara A. Hurvitz, MD, on Updated Survival Results on T-DXd vs T-DM1 in Metastatic Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with...
Expert Point of View: Véronique Diéras, MD
The invited discussant of the phase I/II study of patritumab deruxtecan (HER3-DXd) was Véronique Diéras, MD, of the Eugène Marquis Centre, Rennes, France. She commented that HER3-DXd showed promising activity across breast cancer subtypes with heavily pretreated metastatic breast cancer. She...
Study Finds Patritumab Deruxtecan Active in HER3-Expressing Metastatic Breast Cancer
The HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) showed activity in patients with heavily pretreated HER3-expressing metastatic breast cancer in a phase I/II study. Ian E. Krop, MD, PhD, Associate Director, Yale Cancer Center, New Haven, Connecticut, presented these...
Capturing Tumor Evolution With Serial Biopsies May Guide Treatment Changes to Benefit Patients With Breast Cancer
Molecular testing and genomic testing are now considered standard of care in breast cancer, guiding treatment decisions in early breast cancer and targeted therapies in the metastatic setting. “But tumors evolve,” Virginia Kaklamani, MD, DSc, reminded participants at the 2022 Lynn Sage Breast...
Patient-Reported Outcomes Study Finds Severe Symptoms in Meaningful Minority of Patients With Cancer
Routine monitoring in the real world may help to identify patients with cancer who are experiencing challenging symptoms, without significantly disrupting clinical workload, according to data presented during the 2022 ASCO Quality Care Symposium.1,2 The analysis of nearly 40,000 patient-reported...
Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer
Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this...
Yara Abdou, MD, on Race and Clinical Outcomes in the RxPONDER Breast Cancer Trial
Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breast cancer with one to three involved lymph nodes and a recurrence score of ≤ 25 have worse outcomes...
Study Finds Use of Remote Interventions Improved Adherence to Cancer Screenings Among Women Living in Rural Areas
Remote interventions, particularly a mailed tailored DVD plus telephonic patient navigation, improved adherence to breast, cervical, and colorectal cancer screenings among women living in rural counties in the United States, according to the results of a randomized controlled clinical trial...
Expert Point of View: Jean Lundberg Wright, MD
Invited discussant of the October 2022 ASCO Plenary session, Jean Lundberg Wright, MD, commended the authors on an “extremely well-done study, with findings applicable to patients today in clinics where barriers are not prohibitive.” She also noted several limitations to the currently available...
Silicone Film Dressing May Reduce Acute Radiation Dermatitis in Some Patients With Breast Cancer
A silicone-based polyurethane film dressing (known as Mepitel® Film) appears to be beneficial in reducing skin toxicities caused by radiation treatment, according to data presented during the October 2022 ASCO Plenary Series.1 The results of a phase III trial showed that this film dressing may be...
T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02
Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1), according to results from ...
ASTRO Celebrates Contributions to Radiation Oncology With 2022 Gold Medals and Other Awards
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2022 Gold Medal awards and other high-profile honors during an awards ceremony at the 2022 ASTRO Annual Meeting in San Antonio. ASTRO Gold Medal Wendell R. Lutz, PhD, and Tim R. Williams, MD, FASTRO, were awarded...
ASTRO Issues Updated Guideline on Radiation Therapy for Patients With Endometrial Cancer
The American Society for Radiation Oncology (ASTRO) provided recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer, according to a newly updated clinical guideline published by Harkenrider et al in Practical Radiation Oncology....
T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03
Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
Cancer Drugs and Price Controls: Is It Time?
According to a recent article published in Cancer Epidemiology, Biomarkers & Prevention, cancer care in the United States exceeded $208 billion in 2020 and is expected to surpass $240 billion by 2030.1 These estimates are driven largely by a growing and aging population. The expenditures...
How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer
In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and significantly longer progression-free survival compared to those treated with combination...
Breast Implants After Mastectomy Associated With Very Low Risk of ALCL
The incidence of anaplastic large cell lymphoma (ALCL) has surged in recent years—possibly because of the growing use of textured breast implants. Considering this trend, some patients with breast cancer who undergo mastectomy may wonder if the benefits of getting reconstructive implants are worth...
Sumanta Pal, MD, on Renal Cell Carcinoma: CRISPR-Engineered CAR T Cells in Advanced Disease
Sumanta Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase I results from the COBALT-RCC study, a first-in-human clinical trial exploring CD70 CAR T-cell therapy in patients with clear cell renal cell carcinoma. The agent appeared to show an excellent safety profile with no...
Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy
Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of distant metastatic recurrence compared with tumors from White patients, according to new findings...
Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients With Hormone Receptor–Positive Early-Stage Breast Cancer
Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased risk of distant recurrence—and those with a low score on the Breast Cancer Index may have benefited...
